Furthermore, the same study shows that the simultaneous blockade of ARF1 and RAS activation in prostate cancer is a potential targeted strategy to prevent the development of this type of tumor (Lang et al., 2017). The gene discussed is ARF1; the disease is prostate carcinoma.